🚀 VC round data is live in beta, check it out!
Enorama Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Enorama Pharma and similar public comparables like Hemp & Health, Stem Cells Spin, Rain Forest International, Synergy CHC and more.
Enorama Pharma Overview
About Enorama Pharma
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
Founded
2006
HQ
Employees
9
Website
Financials (FY)
EV
$2M
Enorama Pharma Financials
Enorama Pharma reported last fiscal year revenue of $299K and negative EBITDA of ($7M).
In the same fiscal year, Enorama Pharma generated ($2M) in gross profit, ($7M) in EBITDA losses, and had net loss of ($8M).
Enorama Pharma P&L
In the most recent fiscal year, Enorama Pharma reported revenue of $299K and EBITDA of ($7M).
Enorama Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $299K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (549%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2265%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2293%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2743%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Enorama Pharma Stock Performance
Enorama Pharma has current market cap of $3M, and enterprise value of $2M.
Market Cap Evolution
Enorama Pharma's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $3M | 0.3% | XXX | XXX | XXX | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEnorama Pharma Valuation Multiples
Enorama Pharma trades at 7.3x EV/Revenue multiple, and (0.3x) EV/EBITDA.
Enorama Pharma Financial Valuation Multiples
As of April 19, 2026, Enorama Pharma has market cap of $3M and EV of $2M.
Equity research analysts estimate Enorama Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enorama Pharma has a P/E ratio of (0.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (1.3x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Enorama Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Enorama Pharma Margins & Growth Rates
Enorama Pharma's revenue in the last fiscal year declined by (83%).
Enorama Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Enorama Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (83%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2265%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 170% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1744% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Enorama Pharma Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Enorama Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Hemp & Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Stem Cells Spin | XXX | XXX | XXX | XXX | XXX | XXX |
| Rain Forest International | XXX | XXX | XXX | XXX | XXX | XXX |
| Synergy CHC | XXX | XXX | XXX | XXX | XXX | XXX |
| PMGC Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enorama Pharma M&A Activity
Enorama Pharma acquired XXX companies to date.
Last acquisition by Enorama Pharma was on XXXXXXXX, XXXXX. Enorama Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Enorama Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEnorama Pharma Investment Activity
Enorama Pharma invested in XXX companies to date.
Enorama Pharma made its latest investment on XXXXXXXX, XXXXX. Enorama Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Enorama Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Enorama Pharma
| When was Enorama Pharma founded? | Enorama Pharma was founded in 2006. |
| Where is Enorama Pharma headquartered? | Enorama Pharma is headquartered in Sweden. |
| How many employees does Enorama Pharma have? | As of today, Enorama Pharma has over 9 employees. |
| Is Enorama Pharma publicly listed? | Yes, Enorama Pharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Enorama Pharma? | Enorama Pharma trades under ERMA ticker. |
| When did Enorama Pharma go public? | Enorama Pharma went public in 2016. |
| Who are competitors of Enorama Pharma? | Enorama Pharma main competitors are Hemp & Health, Stem Cells Spin, Rain Forest International, Synergy CHC. |
| What is the current market cap of Enorama Pharma? | Enorama Pharma's current market cap is $3M. |
| What is the current revenue of Enorama Pharma? | Enorama Pharma's last fiscal year revenue is $299K. |
| What is the current EV/Revenue multiple of Enorama Pharma? | Current revenue multiple of Enorama Pharma is 7.3x. |
| Is Enorama Pharma profitable? | No, Enorama Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.